Total Funding
33
51
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
124863
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers.
James L. Freddo: Chief Medical OfficerPast Role: Anadys Pharmaceuticals, Chief Medical Officer and Senior Vice President, Drug Development
Afif Khoury: Investor
About the Company
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.
Oncternal Therapeutics cutting-edge scientific approach is focused on
targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
Women Founded
